Skip to main content

Viloxazine Side Effects

Medically reviewed by Last updated on Apr 4, 2024.

Applies to viloxazine: oral capsule extended release.


Oral route (Capsule)

Warning: Suicidal Thoughts and BehaviorsIn clinical studies, higher rates of suicidal thoughts and behavior were reported in patients with ADHD treated with viloxazine than in patients treated with placebo. Closely monitor all viloxazine-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors.

Serious side effects of Viloxazine

Along with its needed effects, viloxazine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking viloxazine:

More common

Less common

Other side effects of Viloxazine

Some side effects of viloxazine may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Less common

Incidence not known

For Healthcare Professionals

Applies to viloxazine: oral capsule extended release.


The most reported adverse reactions have included somnolence, decreased appetite, fatigue, nausea, vomiting, insomnia, and irritability. The adverse reactions most commonly associated with discontinuation were somnolence, nausea, headache, irritability, tachycardia, fatigue, and decreased appetite.[Ref]

Nervous system

Very common (10% or more): Somnolence (16%), headache (11%)

In short-term, placebo-controlled clinical trials, somnolence (including lethargy and sedation) was reported in 16% of treated patients compared to 4% of placebo patients.


Very common (10% or more): Increase in heart rate (22%), increase in blood pressure (25%)

In patients 6 to 11 years (n=154), 22% of patients treated with this drug at 100 mg/day had a 20 beat per minute (bpm) or greater increase in heart rate at any time point in the clinical trial, compared to 9% of placebo patients (n=159). For the 200 mg dose, an increase in bpm was found in 31% (84/268) of patients receiving the drug compared to 15% (39/262) in the placebo group. These number were 28% (28/100) and 23% (24/103) for patients receiving 400 mg/day and placebo, respectively. For patients 12 to 17 years receiving 200 mg/day, 22% (22/99) had a 20 bpm increase in heart rate at any point in the clinical trial compared to 15/104 (14%) of patients who received placebo. For the 400 mg dose, the percentages were 34% (69/205) and 17% (35/201) in treated patients and placebo, respectively. For patients 12 to 17 years, 25% (52/205) of patients receiving 400 mg/day had a 15 mmHg or greater increase in diastolic blood pressure at any time in the clinical trial, compared to 13% (26/201) of patients in the placebo group.


Common (1% to 10%): Fatigue, pyrexia


Common (1% to 10%): Decreased appetite

Frequency not reported: Weight changes

In short-term, controlled studies (6 to 8 weeks), patients 6 to 11 years gained an average of 0.2 kg compared to a gain of 1 kg in same-aged patients who received placebo. For patients 12 to 17 years, an average of 0.2 kg was lost compared to a weight gain of 1.5 kg in same-aged patients who received placebo.


Common (1% to 10%): Upper respiratory tract infection


Common (1% to 10%): Abdominal pain, nausea, vomiting


Common (1% to 10%): Insomnia, irritability

Uncommon (0.1% to 1%): Suicidal ideation, behavior, or both

In short-term trials, a total of nine patients (0.9%) reported suicidal ideation (n=6), behavior (n=1) or both (n=2). Eight patients reported suicidal ideation or behavior on the Columbia Suicide Severity Rating Scale (C-SSRS), a validated scale that assesses suicide risk. An additional patient treated with this drug reported suicidal behavior during the clinical trials but did not report it on the C-SSRS. Among 463 patients treated with placebo in these studies, two patients (0.4%) reported suicidal ideation on the C-SSRS. No patients treated with placebo reported suicidal behavior. No completed suicides occurred in these trials.

Frequently asked questions


1. (2021) "Product Information. Qelbree (viloxazine)." Supernus Pharmaceuticals Inc

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.